

## Monthly News – October 2011

# Department of Psychiatry

October 24, 2011 Volume 5, Number 10

### General News:

The open enrollment period for 2012 benefits for **UH employees** is 11/7-11/22. A newsletter will be mailed to the homes of eligible employees at the beginning of November to provide information on benefit options, changes and the open enrollment process. Starting Nov. 1, employees can also attend benefits fairs at various [locations](#) throughout the system. These fairs will give employees an opportunity to learn more about our vendors.

Many tools will be available at [UHWellness.org](#) in early November to allow employees to obtain information, research plan options and learn about changes. For additional questions, contact the HR Wellness Center at 1-877-HR1-PLACE (1-877-471-7522) Monday through Friday from 7:30 a.m.-5 p.m.

### Awards and Recognition:

**Dr. Margaret Kotz** passed the International Gambling Counselor Certification Examination in August 2011.

### Comings and Goings:

Welcome to **Dr. Stephen Ruedrich**, who joins the UH department of Psychiatry as “Director of Adult Psychiatry

Division” and “Chief Quality Officer” for the Department of Psychiatry. Dr. Ruedrich is a well-respected colleague who comes to us from MetroHealth Medical Center, where his clinical focus has been adults with developmental disabilities and serious mental illness. Dr. Ruedrich will be working with clinical directors across our many programs in developing quality standards and metrics, as well as assisting with our clinical operations.

### Congratulations:

**Cindy Glenn** welcomed her first grandchild, Mason Alan Shipe, on Thursday 10/07/11. Mason weighed 8 lbs 3 oz. and was 21.5” long.



### Grand Rounds:

**October 28<sup>th</sup>:**  
**Speaker:** Leah Dickstein, M.D.  
**Topic:** POT (Personal and Other Terrorism): It's Origin, Patterns,

Unless Changed to POER (Personal & Other Earned Respect) by All, Worldwide

**November 4<sup>th</sup>:**  
**Speaker:** Richard B. Corradi, M.D.  
**Topic:** The Psychodynamics of Depression

**November 11<sup>th</sup>:**  
**Speaker:** Steven A. Epstein, M.D.  
**Topic:** Psychiatric Aspects of Living Organ Donation

**November 18<sup>th</sup>:**  
**Speaker:** Jon E. Grant, M.D.  
**Topic:** Disordered Gambling: Using Basic Science to Improve Treatment Outcomes

**November 25<sup>th</sup>:**  
**NO GRAND ROUNDS**

### Presentations and Publications:

**Corradi, R. B.** The Role of Identification in Dynamic Psychiatry and Psychotherapy. *Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry*, 39(3) 539-562, 2011.

A study from the "Helping Others" project was accepted for publication at the Journal of Studies on Alcohol and Drugs. It will be published in the November 2011 issue.

**Pagano, M.E., Kelly, J.F., Johnson, S.M., Post, S.G., & Stout, R.L.** (In

press). The influence of religiosity on 12-Step engagement and substance use disorder treatment response among adolescents. JSAD.

**Martha Sajatovic, M.D.** Late-life Bipolar Disorder: A growing and complex challenge. Symposium Chair and Presenter. 15<sup>th</sup> International Psychogeriatric Association Meeting. The Hague, Netherlands. Scheduled for September 6-9, 2011.

**Martha Sajatovic, M.D.** Geriatric Bipolar Disorder. 8<sup>th</sup> National Geropsychiatry Symposium. Istanbul, Turkey. Scheduled for October 13-16, 2011.

## Research:

The Discovery and Wellness Center for Children at University Hospitals Case Medical Center is currently enrolling patients for participation in a clinical trial for children ages 6-12 years with Attention Deficit Hyperactivity Disorder (ADHD) and aggression. Symptoms may include difficulty paying attention, temper tantrums, and initiating physical fights. Treatment may include parent education, study related exams and medication from a doctor who specializes in pediatric mental illness. To learn more about this research study, please call 216-844-3922.

The Discovery and Wellness Center for Children at University Hospitals Case Medical Center is currently enrolling patients between the ages of 13-17 to participate in a research study for the treatment of schizophrenia. Subjects must be diagnosed with schizophrenia or must exhibit symptoms for a minimum of six months. Symptoms may include: paranoia, confused thoughts or disorganized speech. Eligible subjects must have some symptom relief with a previous medication. Study procedures may include a clinical evaluation, medical tests, and

medication provided at no cost. For more information, please call 216.844.3922.

Do you have patients with **schizophrenia** and previous **trouble with the law**?

This is a multicenter, 15-month, prospective, randomized, active-controlled, open-label, flexible dose study of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to treatment failure in adults with schizophrenia who have been recently released from custody/jail. Participants will be randomly assigned to receive either long-acting injectable or oral antipsychotic. ***Participants should continue to receive mental health and medical services from their usual providers while in the study.***

### To participate, individuals must:

- Be age 18 or older with schizophrenia;
- Have been incarcerated (jail or prison) at least twice in the previous 2 years with the last release from the most recent incarceration occurring within the previous 90 days
- Be able to provide written, informed consent to study participation.

### To participate, individuals may NOT:

- Women who are pregnant or breast-feeding, or planning to become pregnant
- Subjects who are actively abusing intravenous drugs within the past 3 months
- Have previous history of lack of response when treated with paliperidone

**For more information contact:**  
Tiffany Williams  
Phone: 216-844-2835

Email:  
[Tiffany.Williams@UHhospitals.org](mailto:Tiffany.Williams@UHhospitals.org)

Do you have patients with **bipolar disorder** who occasionally miss a dose of their medication and are concerned about **weight gain related to their current medication(s)**?

This is an open-label, 12-week, uncontrolled prospective trial of ziprasidone treatments among sub-optimally adherent patients with bipolar disorder. Psychotropic-related weight gain is a common concern among patients with bipolar disorder (BD). This concern affects an individual's satisfaction with treatment and may lead to reduced adherence and illness relapse.

The project will evaluate how switching to ziprasidone may affect patient adherence, drug attitudes, satisfaction with care, and clinical outcomes (psychiatric symptoms, functional status, weight) among BD patients concerned with weight gain.

*Study team will obtain support for ziprasidone switching for the identified psychotropic from the **patient's current care provider who will continue to see the patient and will continue to prescribe other drugs at unchanged dose.***

### To participate, individuals must:

- Have had a diagnosis of Type I or II BD for at least 6 months
- Be on maintenance evidence-based treatment for BD (lithium, antipsychotic, anticonvulsant).
- Have weight gain concerns that the individual believes are related to BD medication treatment.
- Have sub-optimal adherence.

**To participate, individuals may NOT:**

- Be on ziprasidone immediately prior to study enrollment
- Have current substance *dependence*.
- Be at high risk of harm to self or others.
- Be a female who is currently pregnant or breastfeeding.

**For more information contact:**

Melanie Currens

Phone: 216-844-2825

Email:

[Melanie.Currens@UHhospitals.org](mailto:Melanie.Currens@UHhospitals.org)

**The Mood Disorders Program** at

Case Western Reserve

University/University Hospitals is now enrolling participants into a

clinical trial. The trial is looking at

how pioglitazone can treat the symptoms of depression and

metabolic syndrome. Metabolic Syndrome refers to a group of

medical risk factors found in

individuals that may include being

overweight, having high blood

pressure and/or elevated cholesterol

levels, and a family history of heart

disease and/or diabetes.

The trial is enrolling men and women, ages 18 to 70, who have been diagnosed with both bipolar disorder and metabolic syndrome.

All potential participants will be screened for metabolic syndrome at their initial study visit. All

participants will be taking pioglitazone, an FDA approved

medication for the treatment of high blood sugar. Participants

cannot be suffering from Heart

Failure. All visits will be at the

Mood Disorders Program at the W.

O. Walker Building in University

Circle, and the study may last up to

24 weeks. For more information on

the trial, call 216.844.2869

**Save the date:**

**11/09/11 - 11/12/11**

The Eighth Annual International Conference of the Society for Integrative Oncology will be held at the Intercontinental Hotel. For more information:

<http://www.integrativeonc.org/registration#comp>

**Contact:**

**Published by University Hospitals Dept. of Psychiatry**

**DEADLINE FOR NEXT**

**ISSUE:** Friday, 11/11/2011

**CONTACT:** Kate Kilbane

Phone: 216-844-3658

[kate.kilbane@uhhospitals.org](mailto:kate.kilbane@uhhospitals.org)